MIRA INFORM REPORT

 

 

Report No. :

344939

Report Date :

14.10.2015

 

IDENTIFICATION DETAILS

 

Name :

SERDIA PHARMACEUTICALS INDIA PRIVATE LIMITED

 

 

Registered Office :

Serdia House off Dr. S S Rao Road, Parel, Mumbai – 400012, Maharashtra

Tel. No.:

91-22-24162727

 

 

Country :

India

 

 

Financials (as on) :

31.03.2014

 

 

Date of Incorporation :

30.07.1985

 

 

Com. Reg. No.:

11-037001

 

 

Capital Investment / Paid-up Capital :

Rs.47.600 Million

 

 

CIN No.:

[Company Identification No.]

U52310MH1985PTC037001

 

 

IEC No.:

Not Available

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

Not Available

 

 

PAN No.:

[Permanent Account No.]

Not Available

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Subject is engaged in manufacture and marketing of pharmaceutical formulations, based on imported active pharmaceuticals ingredients (API), under license from Les Laboratories Servier.

 

 

No. of Employees :

Not Available [We tried to confirm the number of employees but no one is ready to part any information from the company management]

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (51)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 1100000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Usually correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is a wholly owned subsidiary of “Servier International BV” Virgin Islands British.

 

It was established in the year 1985 and has satisfactory track.

 

The ratings takes into consideration sound financial risk profile of the company marked by debt free capital structure and decent networth base. Further, the company has reported significant increase in its net profit in FY14.

 

Trade relations are fair. Business is active. Payment terms are reported to be usually correct.

 

In view of strong parent support along with decent financial condition, the company can be considered for business dealings with usual terms and conditions.   

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

Not Available

Rating

Not Available

Rating Explanation

Not Available

Date

Not Available

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2015.

 

 

INFORMATION DENIED BY

 

Name :

Mr. Tejas Doshi

Designation :

Deputy Finance Manager

Contact No.:

91-22-24162727

Date :

13.10.2015

 

 

LOCATIONS

 

Registered Office :

Serdia House off Dr. S S Rao Road, Parel, Mumbai – 400012, Maharashtra, India

Tel. No.:

91-22-24162727/ 24196000

Fax No.:

91-22-24162735

E-Mail :

geeta.karnik@in.netgrs.com

Website:

http://www.serdiapharma.com

 

 

DIRECTORS

 

AS ON 29.09.2014

 

Name :

Yanick Martial Girard

Designation :

Director

Address :

21 Union Park, 2nd And 3rd Floor, Union Park, Road No. 4, Khar (West), Mumbai - 400052, Maharashtra, India

Date of Birth/Age :

10.05.1969

Date of Appointment :

26.09.2013

DIN No.:

06688131

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U52310MH1985PTC037001

SERDIA PHARMACEUTICALS INDIA PRIVATE LIMITED

Director

26/09/2013

26/09/2013

-

Active

NO

2

U51397MH1998PTC116694

SERVIER PHARMACEUTICALS (INDIA) PRIVATE LIMITED

Director

26/09/2013

26/09/2013

-

Active

NO

 

 

Name :

Pierre Jean Andriot

Designation :

Director

Address :

13 Avenue De Bretteville, 92200, Neuilly Sur-Seine, Paris - 92200, France

Date of Birth/Age :

29.12.1962

Date of Appointment :

29.09.2014

DIN No.:

06733741

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U52310MH1985PTC037001

SERDIA PHARMACEUTICALS INDIA PRIVATE LIMITED

Director

29/09/2014

18/12/2013

-

Active

NO

2

U51397MH1998PTC116694

SERVIER PHARMACEUTICALS (INDIA) PRIVATE LIMITED

Director

29/09/2014

18/12/2013

-

Active

NO

 

 

Name :

Philippe Louis Marc Malet

Designation :

Director

Address :

72 Rue Gardenat Lapostol, Suresnes - 92150, France

Date of Birth/Age :

13.07.1965

Date of Appointment :

29.09.2014

DIN No.:

06792415

 

 

KEY EXECUTIVES

 

Name :

Geeta Mahadeo Karnik

Designation :

Secretary

Address :

Flat No 305/306 Nirlep House, G.D. Ambekar Marg, Parel Village, Parel, Mumbai - 400012, Maharashtra, India

Date of Birth/Age :

08.04.1973

Date of Appointment :

31.03.2010

PAN No:

AGQPK9602E

 

 

MAJOR SHAREHOLDERS

 

AS ON 29.09.2014

 

Names of Shareholders

 

No. of Shares

Servier International B V, The Netherlands

 

4759999

Nederaine B V Joint With Servier International B V, The Netherlands

 

1

 

 

 

Total

 

4760000

 

 

 

Equity Share Break up (Percentage of Total Equity)

 

AS ON 29.09.2014

 

Category

Percentage

Foreign holdings( Foreign institutional investor(s), Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s) or Overseas Corporate bodies or Others

100.00

Total

100.00

 

 

 

BUSINESS DETAILS

 

Line of Business :

Subject is engaged in manufacture and marketing of pharmaceutical formulations, based on imported active pharmaceuticals ingredients (API), under license from Les Laboratories Servier.

 

 

Products :

Item Code No.

Product Description

30049000

Metabolism products

 

 

Brand Names :

Not Available

 

 

Agencies Held :

Not Available

 

 

Exports :

Not Divulged

 

 

Imports :

Not Divulged

 

 

Terms :

Not Divulged

 

PRODUCTION STATUS: NOT AVAILABLE

 

 

GENERAL INFORMATION

 

Suppliers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Maximum Limit Dealt :

Not Divulged

Experience :

Not Divulged

Remark:

Not Divulged

 

 

Customers :

Reference :

Not Divulged

Name of the Person :

Not Divulged

Contact No.:

Not Divulged

Since How Long Known :

Not Divulged

Maximum Limit Dealt :

Not Divulged

Experience :

Not Divulged

Remark:

Not Divulged

 

 

No. of Employees :

Not Available [We tried to confirm the number of employees but no one is ready to part any information from the company management]

 

 

Bankers :

Banker Name

Not Divulged

Branch Address

Not Divulged

Person Name (With Designation)

Not Divulged

Contact Number

Not Divulged

Name of Account Holder

Not Divulged

Account Number

Not Divulged

Account Since (Date/Year of Account Opening)

Not Divulged

Average Balance Maintained (If Possible)

Not Divulged

Csredit Facilities Enjoyed (If any)

Not Divulged

Account Operation

Not Divulged

Remarks (If any)

Not Divulged

 

 

 

Auditors :

 

Name :

S.R. Batliboi and Co. LLP

Chartered Accountant

Address :

22, Camac Street, Block, 'C' 3rd Floor, Kolkata - 700 016, West Bengal, India 

PAN N Income-tax PAN of auditor or auditor's firm :

AALFS0506L

 

 

Memberships :

Not Available

 

 

Collaborators :

Not Available

 

 

Fellow Subsidiary company:

  • Servier Egypt Industries Limited, Egypt
  • Les Laboratories Servier, France
  • Arts Et Techniques Du Progress, France

 

 

Holding company:

  • Servier International BV, Virgin Islands, British

 

 

Subsidiary company:

  • Servier Pharmaceuticals (India) Private Limited, India [U51397MH1998PTC116694]

 

 

CAPITAL STRUCTURE

 

AS ON 29.09.2014

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

5000000

Equity Shares

Rs.10/- each

Rs.50.000 Million

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

4760000

Equity Shares

Rs.10/- each

Rs.47.600 Million

 

 

 

 

 

FINANCIAL DATA

[all figures are in Rupees Million]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

31.03.2014

31.03.2013

31.03.2012

 

 

 

 

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

47.600

47.600

47.600

(b) Reserves & Surplus

338.322

184.046

177.467

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

385.922

231.646

225.067

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

0.000

0.000

0.000

(b) Deferred tax liabilities (Net)

0.000

0.000

0.000

(c) Other long term liabilities

23.708

63.425

221.564

(d) long-term provisions

0.000

0.000

61.385

Total Non-current Liabilities (3)

23.708

63.425

282.949

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

0.000

0.000

0.000

(b) Trade payables

540.328

281.999

0.000

(c) Other current liabilities

59.157

58.967

60.441

(d) Short-term provisions

273.309

410.612

366.379

Total Current Liabilities (4)

872.794

751.578

426.820

 

 

 

 

TOTAL

1282.424

1046.649

934.836

 

 

 

 

II.          ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

19.740

20.770

20.601

(ii) Intangible Assets

1.426

2.455

1.914

(iii) Capital work-in-progress

0.000

0.000

0.000

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

0.000

0.000

0.000

defered taxassets

0.000

0.000

36.200

Foreign currency monetary item translation difference asset account

31.748

48.477

0.000

(d)  Long-term Loan and Advances

63.307

43.786

51.714

(e) Other Non-current assets

3.822

2.467

4.226

Total Non-Current Assets

120.043

117.955

114.655

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

325.977

262.459

271.837

(c) Trade receivables

240.107

241.336

200.941

(d) Cash and cash equivalents

504.145

372.045

284.499

(e) Short-term loans and advances

86.833

52.262

57.434

(f) Other current assets

5.319

0.592

5.470

Total Current Assets

1162.381

928.694

820.181

 

 

 

 

TOTAL

1282.424

1046.649

934.836

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2014

31.03.2013

31.03.2012

 

SALES

 

 

 

 

Income

NA 

NA 

NA 

 

Other Income

NA 

NA 

NA 

 

TOTAL

NA 

NA 

NA 

 

 

 

 

 

Less

EXPENSES

NA 

NA 

NA 

 

 

 

 

 

 

PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION

152.138

131.469

165.733

 

 

 

 

 

Less

DEPRECIATION/ AMORTISATION

11.090

11.031

8.576

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX

141.048

120.438

157.157

 

 

 

 

 

Less

TAX

(13.228)

113.859

123.377

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX 

154.276

6.579

33.780

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

175.030

168.451

134.670

 

 

 

 

 

 

Balance Carried to the B/S

329.306

175.030

168.450

 

 

 

 

 

 

Earnings / (Loss) Per Share (Rs.)

32.41

1.38

7.10

 

 

CURRENT MATURITIES OF LONG TERM DEBT DETAILS

 

Particulars

 

31.03.2014

31.03.2013

31.03.2012

Current Maturities of Long term debt

NA

NA

NA

Cash generated from operations

NA

NA

NA

Net cash flows from (used in) operations

226.031

149.064

38.983

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2014

31.03.2013

31.03.2012

Return on Total Assets

(PBT/Total Assets}

(%)

11.28

12.07

17.49

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.37

0.52

0.70

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

0.00

0.00

0.00

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.33

1.24

1.92

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Million]

 

DEBT EQUITY RATIO

 

Particular

31.03.2012

31.03.2013

31.03.2014

 

(Rs. In Million)

(Rs. In Million)

(Rs. In Million)

Share Capital

47.600

47.600

47.600

Reserves & Surplus

177.467

184.046

338.322

Net worth

225.067

231.646

385.922

 

 

 

 

long-term borrowings

0.000

0.000

0.000

Short term borrowings

0.000

0.000

0.000

Total borrowings

0.000

0.000

0.000

Debt/Equity ratio

0.000

0.000

0.000

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check list by info agents

Available in Report (Yes/No)

1

Year of establishment

Yes

2

Constitution of the entity -Incorporation details

Yes

3

Locality of the entity

Yes

4

Premises details

No

5

Buyer visit details

--

6

Contact numbers

Yes

7

Name of the person contacted

Yes

8

Designation of contact person

Yes

9

Promoter’s background

Yes

10

Date of Birth of Proprietor / Partners / Directors

Yes

11

Pan Card No. of Proprietor / Partners

No

12

Voter Id Card No. of Proprietor / Partners

No

13

Type of business

Yes

14

Line of Business

Yes

15

Export/import details (if applicable)

No

16

No. of employees

No

17

Details of sister concerns

Yes

18

Major suppliers

No

19

Major customers

No

20

Banking Details

No

21

Banking facility details

No

22

Conduct of the banking account

--

23

Financials, if provided

Yes

24

Capital in the business

Yes

25

Last accounts filed at ROC, if applicable

Yes

26

Turnover of firm for last three years

No

27

Reasons for variation <> 20%

--

28

Estimation for coming financial year

No

29

Profitability for last three years

Yes

30

Major shareholders, if available

Yes

31

External Agency Rating, if available

No

32

Litigations that the firm/promoter involved in

--

33

Market information

--

34

Payments terms

No

35

Negative Reporting by Auditors in the Annual Report

No

 

 

NATURE OF OPERATIONS:

 

Subject ('the Company') is engaged in manufacture and marketing of pharmaceutical formulations, based on imported active pharmaceuticals ingredients (API), under license from Les Laboratories Servier, France

 

The Company is a 100% subsidiary of Servier International BV, a Company incorporated in The Netherlands

 

 

INDEX OF CHARGES: NO CHARGES EXIST FOR COMPANY

 

 

FIXED ASSETS

 

Tangible assets

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

 

Unit

Indian Rupees

US Dollar

1

Rs.62.02

UK Pound

1

Rs.99.89

Euro

1

Rs.73.92

 

 

INFORMATION DETAILS

 

Information Gathered by :

SUV

 

 

Analysis Done by :

KIN

 

 

Report Prepared by :

GTA

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

6

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

6

--PROFITABILITY

1~10

6

--LIQUIDITY

1~10

5

--LEVERAGE

1~10

6

--RESERVES

1~10

6

--CREDIT LINES

1~10

5

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

51

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

s

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.